MOORE CAPITAL MANAGEMENT, LP
13F filer · CIK 1448574 · New York, NY
Summary
MOORE CAPITAL MANAGEMENT, LP reported $6.74B across 745 positions in its 13F for 2026 Q2, filed Aug 14, 2026. The largest holdings are NVDA (1.5%), UBS (1.4%), AMAT (1.3%). Versus 2026 Q1, leaving options aside, it opened 247 new positions, added to 91, trimmed 71 and sold out of 139.
Reported value$6.74B
Positions745incl. options
Report period2026 Q2
FiledAug 14, 2026
New positions247
Added91
Trimmed71
Sold out139
Top 25 holdings
By reported value, options listed separately · change vs 2026 Q1
Weight 1.5%Value $101.26MPrice $227.21Shares 506K +72.51%Since Jun 30 +13.55%
Weight 1.4%Value $92.13MPrice $48.78Shares 1.86M -8.87%Since Jun 30 -1.59%
Weight 1.3%Value $88.37MPrice $512.01Shares 122K +23.71%Since Jun 30 -29.18%
Weight 1.2%Value $81.56MPrice $92.86Shares 706K -2.29%Since Jun 30 -19.56%
Weight 1.1%Value $72.82MPrice $89.45Shares 770KSince Jun 30 -5.41%
Weight 1.1%Value $72.11MPrice $155.89Shares 303KSince Jun 30 -34.55%
Weight 1.0%Value $69.18MPrice $46.60Shares 1.67MSince Jun 30 +12.78%
Weight 1.0%Value $68.97MPrice $119.00Shares 583K +10.00%Since Jun 30 +0.58%
Weight 1.0%Value $67.39MPrice $323.86Shares 156K +404.49%Since Jun 30 -25.26%
Weight 1.0%Value $66.04MPrice $291.25Shares 218K +161.29%Since Jun 30 -3.78%
Weight 0.9%Value $58.01MPrice $46.93Shares 1.22M +349.38%Since Jun 30 -1.26%
Weight 0.8%Value $56.93MPrice $23.07Shares 2.08M +52.85%Since Jun 30 -15.62%
BRIDGEBIO PHARMA INCNo ticker matchNew
Weight 0.8%Value $56.88MPrincipal $31.93M
Weight 0.8%Value $56.56MPrice $37.81Shares 1.23M -28.88%Since Jun 30 -17.71%
Weight 0.8%Value $53.25MPrice $246.67Shares 223K +2.54%Since Jun 30 +3.50%
Weight 0.8%Value $53.00MPrice $196.46Shares 264K +58.08%Since Jun 30 -2.07%
Weight 0.8%Value $50.59MPrice $69.98Shares 687KSince Jun 30 -4.96%
Weight 0.7%Value $47.96MPrice $78.23Shares 555K +640.00%Since Jun 30 -9.48%
Weight 0.7%Value $47.56MPrice $456.94Shares 100K -41.04%Since Jun 30 -4.32%
Weight 0.7%Value $44.25MPrice $30.25Shares 1.01M +140.04%Since Jun 30 -30.92%
Weight 0.7%Value $44.24MPrice $171.17Shares 239KSince Jun 30 -7.58%
Weight 0.6%Value $39.53MPrice $45.66Shares 941KSince Jun 30 +8.69%
Weight 0.6%Value $39.47MPrice $21.39Shares 1.44M -28.14%Since Jun 30 -21.88%
Weight 0.5%Value $35.08MPrice $16.51Shares 1.43MSince Jun 30 -32.61%
Weight 0.5%Value $34.37MPrice $128.72Shares 279KSince Jun 30 +4.40%
| Stock | Weight | Value | Since Jun 30 | Shares change | Action |
|---|---|---|---|---|---|
| 1.5% | $101.26M | +13.55% | +72.51% | Add | |
| 1.4% | $92.13M | -1.59% | -8.87% | Trim | |
| 1.3% | $88.37M | -29.18% | +23.71% | Add | |
| 1.2% | $81.56M | -19.56% | -2.29% | Trim | |
| 1.1% | $72.82M | -5.41% | — | New | |
| 1.1% | $72.11M | -34.55% | — | New | |
| 1.0% | $69.18M | +12.78% | — | New | |
| 1.0% | $68.97M | +0.58% | +10.00% | Add | |
| 1.0% | $67.39M | -25.26% | +404.49% | Add | |
| 1.0% | $66.04M | -3.78% | +161.29% | Add | |
| 0.9% | $58.01M | -1.26% | +349.38% | Add | |
| 0.8% | $56.93M | -15.62% | +52.85% | Add | |
| BRIDGEBIO PHARMA INCNo ticker match | 0.8% | $56.88M | — | — | New |
| 0.8% | $56.56M | -17.71% | -28.88% | Trim | |
| 0.8% | $53.25M | +3.50% | +2.54% | Add | |
| 0.8% | $53.00M | -2.07% | +58.08% | Add | |
| 0.8% | $50.59M | -4.96% | — | New | |
| 0.7% | $47.96M | -9.48% | +640.00% | Add | |
| 0.7% | $47.56M | -4.32% | -41.04% | Trim | |
| 0.7% | $44.25M | -30.92% | +140.04% | Add | |
| 0.7% | $44.24M | -7.58% | — | New | |
| 0.6% | $39.53M | +8.69% | — | New | |
| 0.6% | $39.47M | -21.88% | -28.14% | Trim | |
| 0.5% | $35.08M | -32.61% | — | New | |
| 0.5% | $34.37M | +4.40% | — | New |
Weight is the share of the reported 13F value, including options at notional value. “Since Jun 30” compares the latest close with the quarter-end price implied by the filing (value ÷ shares).
Largest buys in 2026 Q2
BRIDGEBIO PHARMA INCNo ticker match≈ $56.88MNew
Largest sells in 2026 Q2
COINBASE GLOBAL INCNo ticker match≈ $60.81MSold
ETSY INCNo ticker match≈ $45.92MSold
Options
Notional value, listed apart from stocks · top 10 of 30
Source: SEC Form 13F, values as reported by the filer. Filings lag up to 45 days after quarter end and cover only certain long positions. Research only, not investment advice.